Dr. Agarwal's Health Care reported a 44.6% year-on-year surge in consolidated net profit after tax (PAT) to ₹55.02 crore for Q1FY27, driven by robust revenue growth of 26% to ₹614.02 crore. The eye care chain strengthened its operational footing by expanding its network to 304 facilities across 10 countries and executing its largest-ever quarterly expansion of surgical centers. Standalone PAT also grew significantly to ₹16.67 crore from ₹10.11 crore in the same period last year, reflecting improved operating leverage and significant growth in high-margin specialized procedures.

Q1FY27 Financial Performance

The Board of Directors, meeting on August 04, 2026, approved unaudited financial results showing significant top-line and bottom-line improvements across both standalone and consolidated structures. Consolidated revenue from operations grew to ₹614.02 crore from ₹487.42 crore in Q1FY26. Total income rose 23.9% to ₹620.43 crore. Consolidated EBITDA increased by 25.2% to ₹176.82 crore, with margins widening to 28.5% from 28.2%.

Standalone revenue from operations stood at ₹382.62 crore, up from ₹301.72 crore in Q1FY26. Standalone EBITDA reached ₹98.99 crore, compared to ₹79.83 crore previously. Profit after tax (PAT) climbed to ₹16.67 crore from ₹10.11 crore, with PAT margins expanding to 4.4% from 3.3%.

Operational Expansion and Network Growth

As of June 30, 2026, the company’s network expanded to 304 facilities, adding 18 new facilities during the quarter while closing two primary centers in Janipur (Jammu) and Zirakpur (Punjab). This included a record 16 new surgical facilities. The company performed 91,082 surgeries, a 15.5% year-on-year increase from 78,882 in Q1FY26. Cataract surgeries accounted for 67,444 procedures, while refractive surgeries grew to 3,998. The company served over 8.8 lakh patients with a team of 1,057 doctors. CEO Dr. Adil Agarwal highlighted that greenfield losses were contained despite launching 23 surgical facilities in the preceding six months.

Specialized surgical procedures showed strong momentum:

• Femto Cataracts: 1,548 procedures (33.4% YoY growth)
• Lenticular Procedures: 1,712 procedures (36.2% YoY growth)
• Retinal Surgeries: 3,861 procedures (30.0% YoY growth)
• Anterior Segment Reconstruction: 286 procedures (15.8% YoY growth)
• Corneal Transplants: 589 procedures (10.1% YoY growth)

Corporate Governance and Strategic Moves

The Board appointed M/s. S.R. Batliboi & Associates LLP as Statutory Auditors until the conclusion of the 20th AGM, filling a casual vacancy left by Deloitte Haskins & Sells. M/s. KPMG Assurance and Consulting Services LLP was appointed as Internal Auditors for FY2026-27, replacing M/s. R.G.N Price & Co., which had served for seven years. B Y & Associates was re-appointed as Cost Auditors for FY2026-27.

Strategically, the company proposed incorporating a wholly owned subsidiary in Nigeria through its Mauritius entity, Orbit Healthcare Services. The Nigerian entity will engage in comprehensive eye care services subject to regulatory approvals from bodies including the Corporate Affairs Commission (CAC) and Medical and Dental Council of Nigeria (MDCN).

Regarding capital utilization, the Board approved the reallocation of ₹14.88 crore of surplus funds from "IPO expenses" to "General Corporate Purposes" in May 2026. As of June 30, 2026, ₹17.69 crore of fresh issue proceeds remained unutilized, invested in fixed deposits. Additionally, IdeaRx Services Private Limited ceased to be an associate entity effective March 30, 2026, following the termination of shareholder rights under the shareholders' agreement, though the company retains a 14.54% equity stake.

What the Numbers Show

The divergence between revenue growth (26%) and EBITDA growth (25.2%) alongside margin expansion indicates effective operating leverage. The significant rise in consolidated PAT (44.6%) outpacing EBITDA growth suggests favorable tax dynamics or lower interest expenses relative to earnings. The growth in specialized high-margin procedures like Femto Cataracts and Retinal Surgeries supports the margin expansion narrative, demonstrating successful clinical innovation adoption across the network.

Dr. Agarwal's Health Care has released its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The healthcare provider held an analyst and earnings conference call on August 4, 2026, to discuss the operational and financial performance for the period. This disclosure ensures transparency for investors regarding the company’s latest quarterly standing in the eye care sector.

The filing was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dr. Agarwal's Health Care Limited submitted the notice to both BSE Limited and National Stock Exchange of India Limited. The audio recording of the conference call is available on the company’s official website for investor access.

Key Disclosures

The primary focus of the communication was the availability of the earnings call recording detailing the Q4FY26 results. Below are the specific details provided in the regulatory filing:

Thanikainathan Arumugam, Company Secretary and Compliance Officer, signed the disclosure. The document confirms that the audio recording can be accessed via the designated link on the corporate website, ensuring compliance with listing obligations.